Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05480527
Other study ID # Diabetic PNP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date December 1, 2023

Study information

Verified date February 2023
Source Diskapi Teaching and Research Hospital
Contact Gevher Rabia Genc Perdecioglu
Phone 05332009184
Email gevhergenc@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators want to investigate the efficacy of transcutaneous pulsed radiofrequency therapy in the treatment of diabetic peripheral neuropathy symptoms. For this purpose, investigators aimed to compare the results of two groups treated with sham electrode and active electrode.


Description:

Peripheral neuropathic pain is common in diabetes mellitus. Distal symmetrical polyneuropathy is the most common form. These patients have complaints such as burning, freezing, tingling and pain in their hands and feet. Peripheral nerve blocks or sympathetic blocks are applied to patients who cannot be treated with medical agents. Transcutaneous pulsed radiofrequency is a method used in the treatment of pain. The advantages of transcutaneous pulsed radiofrequency method are that it is not invasive, does not cause side effects, and does not interact with drugs. We want to investigate the efficacy of diabetic peripheral neuropathic pain treatment with this method. Sixty diabetic polyneuropathy patients will be included in the study. Transcutaneous pulsed radiofrequency therapy with active electrode will be applied to half of the patients. Sham electrode will be used for the other half. Patients will not know which group they belong to. Two treatments will be applied with 7 days intervals. The duration of treatment will be 8 minutes.Each patient will receive a Leeds Assessment of Neuropathic Symptoms and Signs questionnaire (LANSS). Before the treatment, in the first month and third month after the treatment, the patients will be filled with a visual analog scale. The results between both groups will be statistically compared.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 1, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of Diabetes Mellitus - Peripheric neuropathy with proved electroneuromyography Exclusion Criteria: - Additional endocrinological disease, - Pregnancy, malignancy, motor deficit in lower extremities

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcutaneous pulsed radiofrequency current
Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.

Locations

Country Name City State
Turkey Diskapi Reserch and Education Hospital Ankara

Sponsors (1)

Lead Sponsor Collaborator
Diskapi Teaching and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baselina in pain on the Visual Analog Scale (VAS) at week 4 and 12 The visual analogue scale (VAS) is a scale that can be used measuring pain. Scores range from 0 (no pain) to 10 (the worst pain). Bseline, week 4 and week 12
Secondary Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) it is a 7-item self-report scale developed to identify pain of predominantly neuropathic origin. Scores range 0 and 24. Scores of 12 and above are associated with neuropathic pain baseline, week4 and week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Completed NCT05161364 - Kinetic Analysis Due to Foot Dysfunction
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT02970006 - Investigating Mechanisms Underlying Spinal Cord Stimulation Efficacy Using Virtual Reality and Full Body Illusion N/A
Recruiting NCT05291286 - BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients Early Phase 1
Recruiting NCT04403802 - Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy N/A
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT05624138 - The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy Phase 3
Recruiting NCT06121232 - Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study N/A
Recruiting NCT05065554 - ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy Phase 2
Recruiting NCT05980767 - Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial N/A
Completed NCT03135535 - Micro-mobile Foot Compression and Diabetic Foot Phase 2
Recruiting NCT03037684 - Depolarising Electrical Skin Stimulation in Neuropathic and Postoperative Pain
Recruiting NCT04865185 - Effect of Topical Lidocaine on Warm and Cold Sensation in Healthy Individuals N/A
Completed NCT05093023 - ABCB1 SNPs as Predictors of PIPN
Completed NCT05410548 - Comorbidity Screening and Referral by Prosthetists N/A
Completed NCT03021174 - Exercise and Nutrition Interventions During Chemotherapy N/A
Not yet recruiting NCT06422949 - Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy N/A
Terminated NCT03777956 - The Effect of Lacosamide in Peripheral Neuropathic Pain Phase 2